Sign inJoin waitlistJoin the waitlist

RY

Randy Yeh

Section Chief · Icahn School of Medicine at Mount Sinai

Credentials: · · · · ·

History

Icahn School of Medicine at Mount Sinai
Present
New York Presbyterian Hospital
Present

Nuclear Radiology
New York Presbyterian Hospital
2014–2015
Diagnostic Radiology
2010–2014
Nuclear Medicine
2011–2014
Preliminary Internal Medicine
Olive View/UCLA Medical Center
2009–2010
University of Texas School of Medicine at San Antonio
2005–2009

Research

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of…
The Lancet · 2024 · 251 citations
Prolonged red cell storage before transfusion increases extravascular hemolysis
Journal of Clinical Investigation · 2017 · 179 citations
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Nature Medicine · 2022 · 152 citations

LD
Laurent Dercle
27 papers · 21 as a resident
JD
Jeeban Das
14 papers · 14 as a resident
LS
Lawrence Schwartz
9 papers
Kathleen Capaccione
8 papers · 6 as a fellow
Heiko Schöder
7 papers
GU
Gary Ulaner
6 papers
Jennifer Kuo
6 papers
CP
Conor Prendergast
5 papers · 1 as a resident
Hong Ma
5 papers
Aileen Deng
4 papers
Catherine McManus
4 papers · 4 as a resident
CD
Chaitanya Divgi
4 papers

Grants

HER2 PET Imaging to Assess HER2 Heterogeneity and Predict Response to HER2-Targeted ADC Therapy in Urothelial Carcinoma
National Cancer Institute · R01
PI · $1.7M · Sloan-Kettering Inst Can Research
2024–2029

Clinical trials

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Principal investigator · Not yet recruiting · Phase 2
Randy Yeh
2026–2027
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Principal investigator · Completed · Early phase 1
Memorial Sloan Kettering Cancer Center
2013–2024
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Site PI · Recruiting · Phase 2, Phase 3
Novartis Pharmaceuticals
2025–2033